कंपनी का अवलोकन
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical entity dedicated to the development and commercialization of therapeutic medicines specifically targeting neurological and rare diseases within the North American market. The company's primary commercial asset is NUPLAZID, a selective serotonin inverse agonist/antagonist indicated for the treatment of hallucinations, which anchors its revenue generation strategy. This organization functions within the broader Healthcare sector and the specialized Biotechnology industry, sectors characterized by high innovation requirements and regulatory scrutiny. With a market capitalization of $3.85B, annual revenue of $1.07B, and an employee base of 796, ACADIA demonstrates significant scale relative to many peer biotechnology firms. These valuation and revenue figures indicate that the company has successfully transitioned beyond early-stage research into a commercialization phase capable of generating substantial top-line growth while maintaining a substantial operational workforce.
वित्तीय स्वास्थ्य
The company reported total revenue of $1.07B and net income of $391.00M over the trailing twelve months, while EBITDA stood at $116.57M. The substantial gap between the $1.07B revenue and $391.00M net income reveals a highly efficient cost structure where operating expenses and taxes consume only a fraction of gross sales, resulting in an exceptionally high profit margin. However, the free cash flow stands at $-54,821,124, indicating that despite strong accounting profitability, the company is currently consuming cash, likely due to capital expenditures or working capital requirements associated with scaling commercial operations. The gross margin is reported at 61.0%, reflecting the high value and low variable cost of pharmaceutical products, while the operating margin of 6.1% suggests that overhead costs, such as R&D and sales force expansion, are significant but managed effectively. The profit margin reaches 36.5%, confirming that the majority of revenue translates directly to the bottom line after all operational and non-operational expenses. In terms of balance sheet strength, the company holds $819.69M in cash against only $52.19M in debt, creating a robust liquidity buffer. The debt-to-equity ratio of 4.25 is noted, but the overwhelming cash position suggests the company is not leveraged in a distressed manner despite the ratio appearing high on a mathematical basis. Furthermore, the current ratio of 3.83 indicates exceptional short-term liquidity, meaning the company possesses more than three times the current assets necessary to cover its immediate liabilities. Return on Equity is 39.9% and Return on Assets is 4.8%, metrics that reveal management is highly effective at generating shareholder value from equity investments, although the ROA is moderated by the heavy asset base typical of biotechnology firms.
मूल्यांकन आकलन
The trailing P/E ratio is 9.81, whereas the forward P/E is projected at 24.53, implying that the market expects a significant increase in earnings per share in the coming years to justify the higher forward multiple. The price-to-book ratio stands at 3.13, indicating that the market is willing to pay a substantial premium over the company's net asset value, reflecting confidence in its intellectual property and future cash flows. Additionally, the price-to-sales ratio is 3.59 and the EV/EBITDA is 26.43, which are alternative valuation metrics suggesting the company is priced for high growth rather than current low multiples, a common characteristic in the biotech sector. The stock's 52-week trading range spans from a low of $13.40 to a high of $28.35, providing a clear view of recent volatility and investor sentiment extremes. While the exact current price is not provided in the facts, the forward P/E being more than double the trailing P/E suggests a market expectation of rapid earnings acceleration that will compress the multiple over time. The beta value of 0.83 indicates that the stock's price volatility is lower than the broader market, suggesting it may offer a slightly more stable risk profile than the average large-cap stock during periods of market turbulence.
Growth & Income
ACADIA Pharmaceuticals has demonstrated robust expansion with revenue growth of 9.4% year-over-year and earnings growth of 86.2% year-over-year. The earnings growth rate significantly outpaces the revenue growth rate, which implies improving operational efficiency, favorable pricing power, or a reduction in cost of goods sold that allows profitability to surge faster than sales volume. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders. Instead, ACADIA follows a capital allocation strategy common in the biotechnology industry, where it reinvests all earnings back into the business for research and development, clinical trials, and commercial expansion rather than paying cash dividends. This approach prioritizes long-term growth and asset appreciation over current income generation. The overall growth and income profile is defined by rapid earnings acceleration funded by retained earnings, targeting long-term value creation through product lifecycle management and pipeline expansion in the neurological and rare disease space.